PT-141 (Bremelanotide)
A melanocortin receptor agonist that enhances sexual arousal via CNS pathways. FDA-approved as Vyleesi for hypoactive sexual desire disorder in women.
Quick Reference
- Primary effects
- Mood & Social Ease
- Onset
- 30-60 min (subcutaneous)
- Duration
- 6-12 hours
- Intensity
- Moderate
- Legal status
- Legal (US)
- Evidence level
- Research-backed
Key Compounds
Effects
What you're here for
The Science
Content generated via CMS — mechanism of action, pharmacology, and research summaries will appear here.
Dosage
Content generated via CMS — dosage tiers, timing recommendations, and form-specific guidance will appear here.
Forms & How to Use
Content generated via CMS — available forms (powder, capsule, tincture, etc.) and preparation guidance will appear here.
Safety
Content generated via CMS — contraindications, interactions, and safety profile information will appear here.
Health Disclaimer: This information is for educational purposes only and is not medical advice. Consult a qualified healthcare provider before using any substance, especially if you take medications or have a medical condition.
Legal Status
An interactive legal status map will appear here. Check legality by state and country.
Trusted Vendors
Vendor listings coming soon. We vet every vendor for third-party testing, GMP compliance, and transparent sourcing.
Key Compounds
Sources & Citations
Content generated via CMS — peer-reviewed references, clinical trials, and source links will appear here.